home / stock / idrsf / idrsf short
Short Information | Idorsia AG (OTCMKTS:IDRSF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 86,111 |
Total Actual Volume | 322,662 |
Short Trends | |
---|---|
Cover Days | 9 |
Short Days | 9 |
No Change Days | 2 |
Averages | |
---|---|
Average Short Volume | 4,306 |
Average Short Percentage | 49.85% |
Is there a IDRSF Short Squeeze or Breakout about to happen?
See the IDRSF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-22-2024 | $1.75 | $2.1 | $2.1 | $1.75 | 2,000 | 600 | 30% |
04-05-2024 | $2.6 | $2.74 | $2.74 | $2.6 | 12,000 | 10,000 | 83.33% |
04-04-2024 | $2.75 | $2.75 | $2.75 | $2.75 | 1,506 | 1,506 | 100% |
04-02-2024 | $2.8 | $2.8 | $2.8 | $2.8 | 13,100 | 10,000 | 76.34% |
03-26-2024 | $2.65 | $2.64 | $2.65 | $2.64 | 1,202 | 1,200 | 99.83% |
03-22-2024 | $2.4 | $2.48 | $2.48 | $2.36 | 24,689 | 11,500 | 46.58% |
02-07-2024 | $1.71 | $1.5 | $1.71 | $1.5 | 2,886 | 2,020 | 69.99% |
12-19-2023 | $2.45 | $2.25 | $2.45 | $2.25 | 7,988 | 1,000 | 12.52% |
12-14-2023 | $2.55 | $2.4 | $2.55 | $2.4 | 505 | 100 | 19.8% |
12-11-2023 | $2.38 | $2.2 | $2.38 | $2.1 | 3,500 | 100 | 2.86% |
11-30-2023 | $0 | $2.1 | $0 | $0 | 188,020 | 2,000 | 1.06% |
11-07-2023 | $2.65 | $2.79 | $2.79 | $2.6 | 11,457 | 2,000 | 17.46% |
06-14-2023 | $8.8 | $8.8 | $8.8 | $8.8 | 43,201 | 43,201 | 100% |
03-22-2023 | $11.1 | $11.1 | $11.1 | $11.1 | 251 | 251 | 100% |
03-17-2023 | $12.5 | $12.5 | $12.5 | $12.5 | 267 | 220 | 82.4% |
03-14-2023 | $12 | $12.78 | $12.78 | $12 | 7,210 | 100 | 1.39% |
03-08-2023 | $0 | $13.6 | $0 | $0 | 114 | 10 | 8.77% |
03-02-2023 | $0 | $13.6 | $0 | $0 | 106 | 43 | 40.57% |
03-01-2023 | $13.6 | $13.6 | $13.6 | $13.6 | 160 | 160 | 100% |
02-27-2023 | $12.36 | $12.36 | $12.36 | $12.36 | 2,500 | 100 | 4% |
News, Short Squeeze, Breakout and More Instantly...
Idorsia AG Company Name:
IDRSF Stock Symbol:
OTCMKTS Market:
Ad hoc announcement pursuant to Art. 53 LR Viatris and Idorsia will collaborate on the global development and commercialization of two Phase 3 assets, selatogrel and cenerimod. Idorsia to receive an upfront payment of USD 350 million, potential development and regulatory milestone pay...
Allschwil, Switzerland – November 3, 2023 Idorsia Ltd (SIX: IDIA) announced today that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, were presented as an oral presentati...
Allschwil, Switzerland – June 2 6 , 2023 Idorsia Ltd (SIX: IDIA) today announced that further data for aprocitentan, Idorsia’s investigational dual endothelin receptor antagonist evaluating the treatment of patients with resistant hypertension, were presented as ...